Base de dados : HANSEN Pesquisa : DAPSONA/EF ADV [Descritor de assunto] Referências encontradas : 38 [refinar] Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 2

ir para página

1 / 38

HANSEN

seleciona para imprimir

Id: 27314 Autor: Pavithran, K; Satish, T. C. Título: Dapsone-induced motor polyneuropathy in a patient with leprosy. Fonte: Int. J. Lepr;65(2):262-263, Jun. 1997. . Descritores: Hanseníase Dimorfa/quimioter Dapsona/ef adv Dapsona/uso terap Doença dos Neurônios Motores/ind quim Doença dos Neurônios Motores/diag Limites: Humanos Masculino Feminino Localização: BR191.1

2 / 38

HANSEN

seleciona para imprimir

Id: 25422 Autor: Surur, S. P Título: Drug eruptions and drug reactions ..- Fonte: s.l; s.n; 2003. 2p p. . Descritores: ERUPCAO POR DROGA/clas ERUPCAO POR DROGA/compl ERUPCAO POR DROGA/diag ERUPCAO POR DROGA/etiol PREPARACOES FARMACÊUTICAS/ef adv ERUPCAO POR DROGA/terap - METOTREXATO/ef adv  DAPSONA/ef adv  HANSENIASE/diag Limites: HUMANO Localização: BR191.1; 00896/s

3 / 38

HANSEN

seleciona para imprimir

Id: 25373 Autor: Gokhale, N. R; Sule, R. R; Gharpure, M. B Título: Dapsone syndrome ..- Fonte: s.l; s.n; 1992. 3p p. . Descritores: DAPSONA/admin DAPSONA/ef adv DAPSONA/farmacol DAPSONA/farmacocin DAPSONA/tox DAPSONA/uso terap - HANSENIASE/terap  QUIMIOTERAPIA COMBINADA Limites: HUMANO Localização: BR191.1; 01165/s

4 / 38

HANSEN

seleciona para imprimir Texto Completo-pt

Id: 22772 Autor: Leta, Graziela Carneiro; Simas, Maria Esther Paes de Almeida dos Santos; Oliveira, Maria Leide W. de; Gomes, Maria Katia. Título: Sindrome de hipersensibilidade a dapsona: revisao sistematica dos criterios diagnosticos / Dapsone hypersensitivity syndrome: a systematic review of diagnostic criteria Fonte: Hansen. Int;28(1):79-84, jan.-jun. 2003. tab. Resumo: A importancia mundial da farmacovigilancia vem aumentando, mesmo nos paises subdesenvolvidos. Neste contexto, a sindrome de hipersensibilidade a dapsona (SHD), um efeito colateral raro e potencialmente grave, deve ser considerada, sem, entretanto, comprometer a seguranca da droga e sua ampla utilizacao. Objetivando padronizar os criterios diagnosticos da sindrome, realizou-se uma revisao sistematica da literatura analisando trabalhos, publicados de quinze paises endemicos entre 1956 e 2001. Cento e oito casos foram reportados neste periodo, destes 96,2% apos 1980, com 13,3% de obitos. Neste grupo, 59% apresentaram a sindrome completa - febre, rash, linfadenopatia e hepatite, enquanto 41% expressaram forma incompleta. A taxa de mortalidade do grupo que preenche os criterios de SHD completa foi 9,6% e nao houve associacao estatistica com injuria hepatica. Todavia ressalta-se pouca qualidade dos dados coletados, o que reforca a necessidade de relatos mais precisos em futuras publicacoes. (AU). Descritores: DAPSONA/ef adv HANSENIASE/compl HANSENIASE/terap - SINDROME  HIPERSENSIBILIDADE A DROGAS/clas  HIPERSENSIBILIDADE A DROGAS/diag  HIPERSENSIBILIDADE A DROGAS/fisiopatol Meio Eletrônico: http://hansen.bvs.ilsl.br/textoc/hansenint/v21aov29/2003/PDF/v28n1/v28n1a08.pdf - pt. Localização: BR191.1

5 / 38

HANSEN

seleciona para imprimir

Id: 20765 Autor: Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P Título: Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..- Fonte: s.l; s.n; 2001. 9 p. tab. Resumo: This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU). Descritores: ANEMIA/ind quim ANEMIA/epidemiol CLOFAZIMINA/ef adv DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HEPATITE TOXICA/epidemiol HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/quimioter ESTUDOS RETROSPECTIVOS RIFAMPINA/ef adv RIFAMPINA/uso terap METEMOGLOBINEMIA/ind quim METEMOGLOBINEMIA/epidemiol Limites: HUMANO MASCULINO FEMININO CRIANÇA ADULTO MEIA-IDADE ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 09163/s

6 / 38

HANSEN

seleciona para imprimir

Id: 18503 Autor: Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P Título: Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..- Fonte: s.l; s.n; 2001. 9 p. tab. Resumo: This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU). Descritores: ANEMIA/ind quim ANEMIA/epidemiol CLOFAZIMINA/ef adv DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HEPATITE TOXICA/epidemiol HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/quimioter METEMOGLOBINEMIA/ind quim METEMOGLOBINEMIA/epidemiol ESTUDOS RETROSPECTIVOS RIFAMPINA/ef adv RIFAMPINA/uso terap Limites: HUMANO MASCULINO FEMININO CRIANÇA ADULTO ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 09123/s

7 / 38

HANSEN

seleciona para imprimir

Id: 18489 Autor: Goulart, Isabela Maria Bernades; Arbex, Guilherme Leonel; Carneiro, Marcus Hubaide; Rodrigues, Mariana Scalia; Gadia, Rafael Título: Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia- Fonte: s.l; s.n; set.-out. 2002. 8 p. tab. Resumo: The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem. (AU). Descritores: CLOFAZIMINA/admin CLOFAZIMINA/ef adv DAPSONA/admin DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENIASE/quimioter COOPERACAO DO PACIENTE/estatíst DESISTÊNCIA DO PACIENTE/estatíst ESTUDOS RETROSPECTIVOS RIFAMPINA/admin RIFAMPINA/ef adv Limites: PRÉ-ESCOLAR CRIANÇA ADOLESCENCIA ADULTO RESUMO EM INGLES FEMININO HUMANO LACTENTE RECEM-NASCIDO MASCULINO MEIA-IDADE Localização: BR191.1; 09017/s

8 / 38

HANSEN

seleciona para imprimir

Id: 18476 Autor: Queiroz, Regina Helena Costa; Souza, Ana Maria de; Sampaio, Suely Vilela; Melchior Junior, Enzo Título: Biochemical and hematological side effects of clofazimine in leprosy patients ..- Fonte: s.l; s.n; 2002. 4 p. tab. Resumo: Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients. (AU). Descritores: CONTAGEM DE CELULAS SANGUINEAS CLOFAZIMINA/admin CLOFAZIMINA/ef adv CLOFAZIMINA/uso terap DAPSONA/admin DAPSONA/ef adv DAPSONA/uso terap QUIMIOTERAPIA COMBINADA HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/sangue HANSENIASE/quimioter RIFAMPINA/admin RIFAMPINA/ef adv RIFAMPINA/uso terap Limites: SUPPORT, NON-U.S. GOV'T FEMININO HUMANO MASCULINO Meio Eletrônico: - . Localização: BR191.1; 08998/s

9 / 38

HANSEN

seleciona para imprimir

Id: 18452 Autor: Ognibene, André J Título: Agranulocytosis due to dapsone ..- Fonte: s.l; s.n; apr. 1970. 4 p. ilus, tab. Resumo: Agranulocytosis developed in 16 U. S. soldiers in Vietnam who were receiving daily dapsone prophylaxis for falciparum malaria. The were eight deaths in the group. All patients had been on prophylaxis from 3 weeks to 3 months. recovery or death due to sepsis generally occurred within 9 days. The toxic effects of dapsone have resulted in a limitation in the use of dapsone for prophylaxis of falciparum malaria in U. S. troops in Vietnam.(AU). Descritores: AGRANULOCITOSE/ind quim DAPSONA/ef adv MALARIA/prev MEDICINA MILITAR FATORES DE TEMPO MEDICINA TROPICAL ESTADOS UNIDOS VIETNA Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1; 01870/s

10 / 38

HANSEN

seleciona para imprimir

Id: 18450 Autor: 0, M; Babikr, A; Daneshmend, T. K Título: Dapsone-induced optic atrophy and motor neuropathy ..- Fonte: s.l; s.n; November 01, 1980. 01 p. . Resumo: Blindness is one of the most serious side effects of treatment with drugs. We report a case of a young man who became blind and developed weakness of the legs after inappropriate use of dapsone. This is the first report of optic atrophy in association with daposone.(AU). Descritores: DAPSONA/ef adv NEURÔNIOS MOTORES DOENCAS NEUROMUSCULARES/ind quim ATROFIA OPTICA/ind quim AUTOMEDICACAO/ef adv Limites: RELATO DE CASO HUMANO MASCULINO ADULTO Meio Eletrônico: - . Localização: BR191.1; 00683/s

11 / 38

HANSEN

seleciona para imprimir

Id: 18299 Autor: Helander, I; Partanen, J Título: Dapsone-induced distal axonal degeneration of the motor neurons ..- Fonte: s.l; s.n; 1978. 4 p. . Resumo: Dapsone proved to be effective treatment in a patient who suffered from erthema elevatum diutinum. Serious neurological side effects, however, appeared. The basic mechanism appeared to be a distal axonal degeneration of the motor neurons. Sensory conduction studies were normal in five consecutive EMG examinations. A diagnosis of anemia pernicosa was also made bu the blood values returned to normal after starting B12-vitamin therapy. Penicous anemia seemed not be an etiological factor in the polyneuropathy of our patient because we were not able toshow any damage to the sensory axons.(AU). Descritores: POLINEUROPATIAS/ind quim ERITEMA/quimioter AXÔNIOS/ef drogas NEURÔNIOS MOTORES/ef drogas DEGENERACAO NEURAL DAPSONA/admin DAPSONA/ef adv DAPSONA/uso terap Limites: RELATO DE CASO HUMANO FEMININO ADULTO Meio Eletrônico: - . Localização: BR191.1; 00351

12 / 38

HANSEN

seleciona para imprimir

Id: 18203 Autor: Tomecki, Kenneth J; Catalano, Charles J Título: Dapsone hypersensitivity ..- Fonte: s.l; s.n; jan. 1981. 2 p. . Resumo: A hypersensitivity reaction to low-dose (50-mg), short-term dapsone administration developed in a 16-year-old girl. The reaction included fever, malaise, dermatitis, jaundice with hepatic dysfunction, lymphadenopathy, and hemolytic anemia. Physicians should be familiar with this sulfone syndrome, an uncommon, potentially serious, side effect of dapsone therapy.(AU). Descritores: ACNE VULGAR/quimioter ANEMIA HEMOLITICA/etiol DAPSONA/ef adv ERUPCAO POR DROGA/etiol HIPERSENSIBILIDADE A DROGAS/diag HEPATITE TOXICA/etiol DOENCAS LINFATICAS/ind quim SINDROME Limites: RELATO DE CASO HUMANO FEMININO ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 00741/s

13 / 38

HANSEN

seleciona para imprimir

Id: 17947 Autor: Ramu, G; Sreevatsa; Sengupta, U; Desikan, K. V Título: Evaluation of multiple regimens in leprosy ..- Fonte: s.l; s.n; apr. 1981. 7 p. tab, graf. Resumo: Assessment of bacteraemia has been made at weekly intervals in 36 lepromatous leprosy patients who were put on different antileprosy drug under four regimens, viz., DDS alone, DDS in combination with rifampicin (DDS + RIF), clofazimine (DDS + CLF) and thiacetazone (DDS + TCT). In general, with the continuation of treatment the bacillary load in the blood decreased considerably while bacteriological index (BI) of the skin remained constant during the study. No significant difference was noted in M. leprae clearance from blood between the groups treated with DDS alone and groups treated in combination with CLF and TCT. However, DDS + RIF treatment was most efficient in clearing acid-fast bacilli (AFB) from blood as compared to those noted with other drug regimens.(AU). Descritores: HANSENIASE/quimioter RIFAMPINA/admin SEPTICEMIA/quimioter QUIMIOTERAPIA COMBINADA DAPSONA/ef adv TIOACETAZONA/admin CLOFAZIMINA/admin - AVALIACAO DE MEDICAMENTOS Limites: ESTUDO COMPARATIVO HUMANO MASCULINO Meio Eletrônico: - . Localização: BR191.1; 00696/s

14 / 38

HANSEN

seleciona para imprimir

Id: 17923 Autor: Rasbridge, Marian R; Scott, G. L Título: The haemolytic action of dapsone: the effect on red-cell glycolysis ..- Fonte: s.l; s.n; feb. 1973. 13 p. tab, graf. Resumo: Some aspects of red-cell matabolism were studied in blood samples taken from patients on long-term dapsone therapy. Glucose consumption by the Embden-Meyerhof pathway (EMP) was not abnormal and adenosine-triphosphate (ATP) levels lay within the normal range and were well maintained during incubation. Hexose monophosphate patchway (HMP) activity was increased above that which would be expected from the age of the red-cell population. Red-cell reduced glutathione (GSH) levels tended to be lower than normal, proportional to the dose od dapsone and GSH levels were unstable on incubation. Red-cell fractionation studies showed that the older cell fraction had lower GSH levels and more Heinz bodies but proportionally greater HMP activity than the younger cell fraction. It is suggested that the low GSH levels are probably due to the binding of GSH to sulphydryl groups in haemoglobin and possibly the red-cell membrane. The increased HMP activity in the older cells many, in part, be a compensatory mechanism.(AU). Descritores: ADENOSINA TRIFOSFATO/sangue DAPSONA/ef adv DAPSONA/farmacol DERMATITE HERPETIFORME/quimioter ENVELHECIMENTO ERITROCITICO ERITROCITOS/enzimol ERITROCITOS/metab GLUCOSEFOSFATO DESIDROGENASE/sangue GLUTATIONA/sangue CORPOS DE HEINZ Meio Eletrônico: - . Localização: BR191.1; 01856/s

15 / 38

HANSEN

seleciona para imprimir

Id: 17919 Autor: Rasbridge, Marian M; Scott, G. L Título: The haemolytic action of dapsone: changes in the red-cell membrane ..- Fonte: s.l; s.n; feb. 1973. 11 p. tab, graf. Resumo: Some aspects of red-cell membrane structure and function have been investigated in patients with haemolysis due to dapsone (4,4' diaminodiphenylsulfone). Osmotic fragility and potassium flux were not increased but red-cell membrane changes occurred which suggest instability. These included loss of phospholipid, decrease in acetylcholinesterase activity and increased autohaemolysis. In addition, there was evidence for lipid peroxidation, which might have been the primary lesion. Red-cell membrane sulphydryl group activity was either reduced or altered because these cells were abnormally sensivite to the action of the sulphydryl group inhibitor p-chloromercuribenzoate, as measured by increased potassium leakage and haemolysis. Dapsone also caused abnormal peroxide lysis in the presence of normal hydrogen peroxide detoxification mechanisms and in the absence of vitamin E deficiency. This was prevented by excess vitamin E but not by the sulphydryl compounds, reduced glutathione or cysteine, and it was increased by previous treatment with p-chloromercuribenzoate. It is suggested that the reduced membrane sulphydryl group activity, probably due to the formation of mixed disulphides with precipitated haemoglobin, and lipid proxidation may be responsible for in vitro and, possibly, in vivo dapsone-induced haemolysis.(AU). Descritores: ACETILCOLINESTERASE/sangue MEMBRANA CELULAR/ef drogas DAPSONA/ef adv DERMATITE HERPETIFORME/quimioter HEMOLISE/ef drogas LIPIDIOS/metab FRAGILIDADE OSMOTICA PEROXIDOS/metab FOSFOLIPIDIOS/sangue COMPOSTOS DE SULFIDRILA Limites: MASCULINO FEMININO MEIA-IDADE Meio Eletrônico: - . Localização: BR191.1; 01857/s

16 / 38

HANSEN

seleciona para imprimir

Id: 17898 Autor: Tomecki, Kenneth J; Catalano, Charles J Título: Dapsone hypersensitivity ..- Fonte: s.l; s.n; jan. 1981. 2 p. . Resumo: A hypersensitivity reaction to low-dose (50-mg), short-term dapsone administration developed in a 16-year-old girl. The reaction included fever, malaise, dermatitis, jaundice with hepatic dysfunction, lymphadenopathy, and hemolytic anemia. Physicians should be familiar with this sulfone syndrome, an uncommon, potentially serious, side effect of dapsone therapy.(AU). Descritores: ACNE VULGAR/quimioter ANEMIA HEMOLITICA/etiol DAPSONA/ef adv ERUPCAO POR DROGA/etiol HIPERSENSIBILIDADE A DROGAS/diag HEPATITE TOXICA/etiol DOENCAS LINFATICAS/ind quim SINDROME Limites: RELATO DE CASO HUMANO FEMININO ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 00724/s

17 / 38

HANSEN

seleciona para imprimir

Id: 17810 Autor: Jopling, W. H Título: The treatment of leprosy and its acute complications ..- Fonte: s.l; s.n; jan. 1973. 4 p. tab. Resumo: The first thing to be decided in treating a leprosy patient is whether to admit him to a leprosarium or to treat him on an out-patient basis. However, the question of admission does not arise if the leprosy is indeterminate, tuberculoid, or borderline, for these types of leprosy do not carry a public health risk as nasal scrapings are negative for leprosy bacilli.(AU). Descritores: DAPSONA/ef adv DAPSONA/uso terap EPISTAXE/etiol EPISTAXE/terap ANTIGENO DE MITSUDA HANSENIASE/compl HANSENIASE/imunol HANSENIASE/terap SULFONAMIDAS/uso terap SULFONAS/uso terap Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1; 02019/s

18 / 38

HANSEN

seleciona para imprimir

Id: 16689 Autor: Browne, S. G Título: Drug resistance in leprosy ..- Fonte: s.l; s.n; jan. 1979. 5 p. . Descritores: HANSENIASE DAPSONA DAPSONA Localização: BR191.1; 0445/f

19 / 38

HANSEN

seleciona para imprimir

Id: 15760 Autor: Malfará, Wilson Roberto; Pereira, Carolina Paula; Santos, Antonio Cardoso Dos; Queiroz, Regina Helena Costa Título: Effects of H2-receptor antagonists on dapsone-induced methaemoglobinaemia in rats ..- Fonte: s.l; s.n; 2002. 5 p. tab, graf. Descritores: DAPSONA DAPSONA HANSENIASE HANSENIASE Limites: ANIMAL RATOS Localização: BR191.1; 08449/s

20 / 38

HANSEN

seleciona para imprimir

Id: 15739 Autor: Paniker, Uma; Levine, Norman Título: Dapsone and sulfapyridine ..- Fonte: s.l; s.n; 2001. 8 p. ilus, tab. Descritores: HANSENIASE DERMATOPATIAS ANTIINFECCIOSOS ANTIINFECCIOSOS ANTIINFECCIOSOS ANTIINFECCIOSOS ANTIINFLAMATORIOS NAO ESTEROIDES ANTIINFLAMATORIOS NAO ESTEROIDES ANTIINFLAMATORIOS NAO ESTEROIDES ANTIINFLAMATORIOS NAO ESTEROIDES DAPSONA DAPSONA DAPSONA DAPSONA AGENTES DERMATOLOGICOS AGENTES DERMATOLOGICOS AGENTES DERMATOLOGICOS AGENTES DERMATOLOGICOS SULFAPIRIDINA SULFAPIRIDINA SULFAPIRIDINA SULFAPIRIDINA Localização: BR191.1; 08475/s

---

página 1 de 2

ir para página

Refinar a pesquisa

Base de dados : HANSEN

Formulário avançado

Pesquisar por : Formulário livre

		Pesquisar	no campo
1			PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
2	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
3	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro

Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information